MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/flgastro-2018-101146

Медицинская библиотека · Frontline gastroenterology · 2019

Immunotherapy-related hepatitis: real-world experience from a tertiary centre.

Cheung Vincent, Gupta Tarun, Payne Miranda, Middleton Mark R, Collier Jane D, Simmons Alison, Klenerman Paul, Brain Oliver, Cobbold Jeremy F

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVE

Immune checkpoint inhibitors like anti-programmed cell death protein 1 (PD-1) drugs Nivolumab and Pembrolizumab and anti-cytotoxic T-lymphocyte associated (CTLA-4) drug Ipilimumab have become standard of care in many metastatic cancers. Immunotherapy-related hepatitis and cholangitis present a diagnostic and management challenge, being rare and incompletely characterised. We aim to report the incidence, features and treatments used for this in a real-world setting and to identify useful biomarkers, which can be used to predict effective use of steroids.

DESIGN

Retrospective review of 453 patients started on immunotherapy over 7 years.

SETTING

Tertiary hepatology and oncology centre.

PATIENTS: 21 patients identified with immunotherapy-related hepatotoxicity.

RESULTS

Hepatitis was most common in those receiving dual therapy (incidence 20%), with 75% of Grade 4 hepatitis cases occurring with ipilimumab-containing regimens. Corticosteroid monotherapy is first line treatment, but doses above 60 mg OD prednisolone do not demonstrate any additional benefit in time to hepatitis resolution. The alanine transaminase (ALT) reduction in steroid-responsive hepatitis is typically rapid (with a halving of ALT within 11 days). The commencement of additional immunosuppression (typically mycophenolate) appears safe and prompts a more rapid fall in ALT than corticosteroid use alone. Infliximab was safely used twice as hepatitis treatment. We also describe one patient with rare immunotherapy-induced biliary disease.

CONCLUSIONS

Vigilance is required for detection of immunotherapy-associated liver disease as, other than dual immunotherapy, we can identify no predictive factors for its development. Our data suggest that corticosteroid response is not dependent on the higher dosing regimens. Early escalation of immunosuppression may be of benefit in the absence of a rapid response to corticosteroids.

Для цитирования: Cheung Vincent, Gupta Tarun, Payne Miranda, Middleton Mark R, Collier Jane D, Simmons Alison, Klenerman Paul, Brain Oliver, Cobbold Jeremy F. Immunotherapy-related hepatitis: real-world experience from a tertiary centre.. Frontline gastroenterology. 2019. DOI: 10.1136/flgastro-2018-101146.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.